This bill amends Title XVIII of the Social Security Act to create an explicit Medicare benefit for treatments for dialysis-related amyloidosis (DRA). It defines covered treatments as FDA‑approved items or services furnished in dialysis facilities (freestanding or hospital-based), including necessary adjunct supplies and services, and removes those treatments from the definition of renal dialysis services used in ESRD payment rules.
The bill also directs Medicare to pay for those DRA treatments separately — outside the ESRD prospective payment or composite fee — at 100 percent of the reasonable charges. The change aims to remove a financial disincentive for facilities and clinicians to provide costly, FDA‑approved DRA therapies, but it will shift cost and administrative burdens onto Medicare and require CMS to implement new claims, coding, and oversight rules quickly after enactment.
At a Glance
What It Does
The bill adds a new Medicare benefit category for treatments for dialysis‑related amyloidosis, defines those treatments in statute, excludes them from the existing ESRD renal dialysis services definition, and requires separate payment rather than inclusion in the ESRD prospective payment system.
Who It Affects
Directly affects dialysis facilities (freestanding and hospital‑based), clinicians who administer DRA therapies, manufacturers of FDA‑approved DRA products, and the Medicare program (CMS and beneficiaries with end‑stage renal disease). It also affects ESRD payment administrators and Medicare contractors handling claims and audits.
Why It Matters
By carving DRA treatments out of the ESRD bundle and guaranteeing full reimbursement, the bill removes a common barrier facilities cite for not offering newer, expensive therapies. That may increase patient access but also creates an open spending channel that CMS must manage operationally and financially.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The legislation creates a statutory hook in Medicare to recognize and pay for treatments tailored to dialysis‑related amyloidosis. It does this by adding a new covered‑item subparagraph to the catalog of Medicare benefits and by inserting a specific statutory definition that limits coverage to products approved by the Food and Drug Administration and furnished in dialysis facilities.
The definition also captures supplies and services that are adjunct to and necessary for the therapy.
Crucially, the bill removes those therapies from the existing legal definition of ‘‘renal dialysis services’’ used to calculate ESRD composite rates and prospective payments. Instead of being folded into the ESRD bundle, the treatments must be billed and reimbursed separately.
The statute dictates payment at 100 percent of the reasonable charge for those items and services, which is different from the usual per‑treatment or bundled approach for outpatient dialysis care.Because these changes are statutory and take effect on enactment, CMS will need to establish billing codes, modify claims processing rules, and set criteria for ‘‘reasonable charges’’ and for recognizing when a supply or service is legitimately ‘‘adjunct and necessary.’ü The restriction that treatments be FDA‑approved and furnished in dialysis facilities narrows the coverage pathway — it favors on‑label products administered within the dialysis setting and excludes off‑label or community‑based administration unless the product is FDA‑approved and the care occurs in a dialysis facility.Operationally, facilities that elect to provide DRA therapies will need to adapt their billing workflows to capture separate claims outside the ESRD PPS, while CMS and Medicare contractors will need to monitor utilization, price setting, and potential upcoding or misclassification that could arise from the new carve‑out.
The Five Things You Need to Know
The bill adds a new covered‑item subparagraph (labeled as (KK)) to section 1861(s)(2) of the Social Security Act to include ‘‘treatments for dialysis‑related amyloidosis.’, It inserts a new statutory definition at section 1861(nnn): covered DRA treatments must be FDA‑approved, furnished in a dialysis facility (freestanding or hospital‑based), and include adjunct supplies or services necessary for the treatment.
The bill amends the ESRD statute (section 1881(b)(14)(B)) to exclude DRA treatments from the statutory definition of renal dialysis services, preventing inclusion in the ESRD composite or prospective payment.
Medicare payment law (section 1833(a)(1)(E)) is amended to bar counting DRA treatments toward any prospective payment or comprehensive ESRD fee and to require separate reimbursement at 100% of the reasonable charges for those items and services.
All statutory changes take effect on the date of enactment, obligating CMS to operationalize new billing, coding, and payment procedures immediately upon the law’s effective date.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adds DRA treatments to Medicare’s covered‑items list
This provision inserts a new subparagraph into the statutory list of Medicare‑covered items and services, formally placing ‘‘treatments for dialysis‑related amyloidosis’’ on the Medicare benefit schedule. Practically, that gives CMS a clear statutory basis to develop coverage and payment rules specifically for these treatments rather than relying on more general benefit categories or ad hoc policy decisions. Facilities and manufacturers gain legal clarity that these therapies can be treated as Medicare benefits when the other statutory conditions are met.
Defines what counts as a DRA treatment
The bill creates a tight statutory definition: to qualify, an item or service must (1) be approved by the FDA for treatment of dialysis‑related amyloidosis, (2) be furnished in a dialysis facility (freestanding or hospital‑based), and (3) include any adjunct supplies or services necessary for the treatment. The hospital/facility limitation and the on‑label FDA requirement narrow the coverage to regulated products and in‑setting care, which affects access for therapies given in other settings or used off‑label. CMS will have to decide how to interpret ‘‘adjunct and necessary’’ when adjudicating claims.
Removes DRA treatments from the ESRD bundle
By amending the renal dialysis services definition, the bill prevents DRA therapies from being folded into the ESRD prospective payment system (PPS) or composite rate. That is an important mechanical change: it stops CMS from treating expensive DRA items as part of the facility’s bundled payment, which previously could discourage hospitals or clinics from offering them. The flip side is that removing items from the bundle creates a separate reimbursement pathway that requires parallel administrative and oversight systems.
Guarantees separate payment at full reasonable charges
This language mandates that Medicare pay for qualifying DRA treatments ‘‘separately in the amount of 100 percent of the reasonable charges.’’ It expressly forbids including those treatments in any prospective payment amount or comprehensive fee under section 1881. That leaves CMS with two immediate tasks: define and implement ‘‘reasonable charge’’ methodologies for these items, and create or adopt CPT/HCPCS codes and payment processing rules to pay claims outside the ESRD PPS.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries on dialysis with DRA — Patients diagnosed with dialysis‑related amyloidosis gain a clear Medicare coverage path for FDA‑approved therapies administered in dialysis facilities, reducing the chance that cost‑concerns prevent access.
- Dialysis facilities that provide DRA therapies — Facilities can bill separately for these treatments at full reasonable charges, removing a financial disincentive created by bundling in the ESRD composite rate and potentially making it economical to add the service.
- Manufacturers of FDA‑approved DRA products — The statute creates a predictable Medicare reimbursement channel for on‑label products administered in dialysis units, improving market access and commercial planning for sponsors.
- Nephrologists and dialysis clinicians — Clinicians gain greater ability to recommend and deliver FDA‑approved DRA treatments without relying on facility cross‑subsidies or absorbing drug costs, which should simplify care decisions.
Who Bears the Cost
- Medicare Trust Funds and taxpayers — Paying 100% of reasonable charges for potentially high‑cost therapies creates direct upward pressure on Medicare spending relative to bundling and could increase Part B/overall Medicare expenditures.
- CMS and Medicare contractors — CMS must set up coding, claims processing, pricing, and oversight for a new carve‑out, requiring IT changes, new LCDs or NCDs, and audit resources without appropriation in the bill.
- Dialysis facilities’ billing and compliance operations — Facilities need to implement new billing workflows, update EMRs and claims systems, and potentially handle more prior authorization and documentation requests, increasing administrative burden and cost.
Key Issues
The Core Tension
The central dilemma is between assuring patient access to potentially high‑cost, FDA‑approved therapies by guaranteeing full, separate Medicare payment, and preserving Medicare’s ability to control spending and maintain integrated, bundled incentives in ESRD care. Expand coverage and you reduce access barriers — but you also create a direct spending pathway and administrative complexity that can encourage high prices and fragmented care.
The bill solves a clear access problem by assuring separate reimbursement, but it leaves several operational and policy questions unresolved. First, ‘‘reasonable charges’’ is a legacy Medicare term that requires CMS to determine an applicable methodology (e.g., average sales price, weighted average, or fee schedule equivalents) for potentially novel therapies; the statute does not constrain pricing or require utilization controls such as prior authorization or step therapy.
That gap could let manufacturers leverage single‑payer coverage to support high launch prices, creating large Medicare liabilities.
Second, the facility‑based limitation and the narrow FDA‑approval requirement reduce ambiguity but may also exclude clinically useful off‑label uses or therapies administered in other settings (ambulatory clinics, infusion centers, or hospitals not billing as dialysis facilities). The bill also does not define how CMS should resolve disputes over whether an item or service is ‘‘adjunct and necessary,’’ which is likely to generate claims denials and appeals until CMS issues formal guidance.
Lastly, by carving DRA treatments out of the ESRD bundle, the law fragments the payment model: facilities may have new revenue opportunities that change clinical incentives and complicate integrated care pathways for dialysis patients, while CMS loses the simplicity of bundled payments that drive cost containment.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.